Donate
Call the Lung HelpLine
Ask a Question
The following text field filters the results that follow as you type. Use Tab to access the results.
  1. Home
  2. Research & Reports
  3. About Our Research
  4. Research News
  5. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate

Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19

Journal of the American Medical Association | January 12, 2023

This study found that Fluvoxamine, a drug used for psychiatric conditions with anti-inflammatory properties, did not reduce recovery time in patients with symptomatic mild to moderate COVID-19. These findings are important because it advances research into oral treatments for COVID-19 and directs clinicians to other avenues of treatment. Co-author Mario Castro, MD, MPH serves on the Lung Association Scientific Advisory Committee and is an ACRC investigator.
Community Connections: Lung Cancer: Challenges in Molecular Testing
, | May 26, 2026 Tobacco Basics
, | Jun 24, 2026
See All Events